Literature DB >> 2308344

Protein binding of the contraceptive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in human serum.

W Kuhnz1, M Pfeffer, G al-Yacoub.   

Abstract

The protein binding of ethinylestradiol (EE2), gestodene (GEST) and 3-keto-desogestrel (KDG) has been determined by ultrafiltration in the serum of women who had either taken a gestodene (n = 37) or desogestrel (n = 28) containing oral contraceptive for a time period of at least 3 months. GEST and KDG were analyzed in individual serum pools whereas EE2 was repeatedly measured in two serum pools, each one representing one treatment group. The respective free fractions of the three steroids were 0.6 +/- 0.1% (GEST), 2.5 +/- 0.2% (KDG), 1.7 +/- 0.6% (EE2, in the gestodene-group) and 1.5 +/- 0.2% (EE2, in the desogestrel-group). EE2 was exclusively bound to albumin, whereas GEST and KDG were also bound to sex-hormone-binding globulin (SHBG). The distribution of the two progestins over the serum binding proteins was determined after heat-treatment of serum samples. For GEST, the contribution of albumin and SHBG was 24.1 +/- 9.1 and 75.3 +/- 9.1%, respectively and for KDG it was 65.9 +/- 11.9 and 31.6 +/- 12.0%, respectively. SHBG and corticosteroid-binding globulin (CBG) concentrations were measured in the serum samples obtained from both treatment groups. In the gestodene-group 180 +/- 61 nmol/l (SHBG) and 89 +/- 13 mg/l (CBG) were measured, the corresponding values in the desogestrel-group were 226 +/- 64 nmol/l (SHBG) and 93 +/- 14 mg/l (CBG). SHBG concentrations were correlated with the total concentration of GEST and its free fraction and a positive (r = 0.395) and negative (r = -0.491) correlation respectively was found. Only a weak negative correlation (r = -0.291) was found for SHBG and the free fraction of KDG in the serum. These data demonstrate that the three contraceptive steroids EE2, GEST and KDG were all bound extensively to serum proteins, however, with pronounced differences concerning their distribution over the various binding proteins.

Entities:  

Keywords:  Biology; Contraception; Contraceptive Agents, Estrogen--analysis; Contraceptive Agents, Female--analysis; Contraceptive Agents--analysis; Data Analysis; Endocrine System; Ethinyl Estradiol--analysis; Examinations And Diagnoses; Family Planning; Hematological Effects; Hemic System; Hormones--analysis; Laboratory Examinations And Diagnoses; Physiology; Research Methodology; Serum Protein Effects

Mesh:

Substances:

Year:  1990        PMID: 2308344     DOI: 10.1016/0022-4731(90)90290-9

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  8 in total

1.  Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women.

Authors:  Carolyn L Westhoff; Anupama H Torgal; Elizabeth Rose Mayeda; Kelsey Petrie; Tiffany Thomas; Monica Dragoman; Serge Cremers
Journal:  Am J Obstet Gynecol       Date:  2012-04-28       Impact factor: 8.661

2.  Comparing the androgenic and estrogenic properties of progestins used in contraception and hormone therapy.

Authors:  Renate Louw-du Toit; Meghan S Perkins; Janet P Hapgood; Donita Africander
Journal:  Biochem Biophys Res Commun       Date:  2017-07-12       Impact factor: 3.575

Review 3.  Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations.

Authors:  M I Wilde; J A Balfour
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 4.  Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.

Authors:  Frank Z Stanczyk; Janet P Hapgood; Sharon Winer; Daniel R Mishell
Journal:  Endocr Rev       Date:  2012-12-13       Impact factor: 19.871

5.  Comparison of life-stage-dependent internal dosimetry for bisphenol A, ethinyl estradiol, a reference estrogen, and endogenous estradiol to test an estrogenic mode of action in Sprague Dawley rats.

Authors:  Mona I Churchwell; Luísa Camacho; Michelle M Vanlandingham; Nathan C Twaddle; Estatira Sepehr; K Barry Delclos; Jeffrey W Fisher; Daniel R Doerge
Journal:  Toxicol Sci       Date:  2014-02-04       Impact factor: 4.849

Review 6.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

7.  Risk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach.

Authors:  Udoamaka Ezuruike; Helen Humphries; Maurice Dickins; Sibylle Neuhoff; Iain Gardner; Karen Rowland Yeo
Journal:  Clin Pharmacol Ther       Date:  2018-04-27       Impact factor: 6.875

Review 8.  In Vitro Methods for Evaluating Drug Release of Vaginal Ring Formulations-A Critical Review.

Authors:  Katharina Tietz; Sandra Klein
Journal:  Pharmaceutics       Date:  2019-10-16       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.